Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

As­traZeneca’s com­pet­i­tive threat to Amarin’s mighty Vas­cepa in pa­tients with car­dio­vas­cu­lar risk has wilt­ed.

On Mon­day, the British drug­mak­er said it was aban­don­ing a large car­dio­vas­cu­lar (CV) out­comes tri­al test­ing its fish oil pill Epano­va af­ter an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee pre­dict­ed the ther­a­py had a low like­li­hood of demon­strat­ing a ben­e­fit to pa­tients with mixed dys­lip­i­daemia who car­ry a high risk of CV dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.